<DOC>
	<DOCNO>NCT02969044</DOCNO>
	<brief_summary>This 8 week study ass efficacy safety profile PF-06651600 seropositive subject rheumatoid arthritis inadequate response methotrexate ( approximately 50 % subject may also inadequate response 1 anti-TNF biologic ) .</brief_summary>
	<brief_title>Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Inclusion Criteria Subjects age 18 75 year , inclusive Must moderatetosevere , active Rheumatoid Arthritis Must inadequate response Methotrexate Subjects may receive one approve TNF inhibit biologic agent inadequately effective and/or tolerate Exclusion Criteria Subjects acute chronic infection infection history Have acute active chronic dermatological disorder prior study start Any major illness/condition ( ) evidence unstable clinical condition judgment investigator would make subject inappropriate entry study Known immunodeficiency disorder first degree relative hereditary immunodeficiency Any live ( attenuate ) vaccine current routine household contact anyone receive live ( attenuate ) vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>